Paroxetine: uses, dosing, side effects & brands

Paxil (Paroxetine Hydrochloride) is a serotonin reuptake inhibitor used to treat Feeding and Eating Disorders, Depressive Disorder, Obsessive-Compulsive Disorder, Phobic Disorders.

The FDA classifies paroxetine as a serotonin reuptake inhibitor. Selective serotonin reuptake inhibitors (SSRIs) block the transporter that pulls serotonin back into nerve cells, so more of this mood-related chemical stays in the gaps between neurons to keep signaling. They act mainly on serotonin, which tends to mean fewer side effects than older antidepressants. If you are checking whether it is safe to combine with something else, the class is what matters — two drugs from the same class usually should not be stacked.

The label describes specific reported risks rather than reassurance. Based on published observational studies, first-trimester paroxetine use is associated with a less than 2-fold increase in cardiovascular malformations (meta-analyses report inconsistent overall findings but an increased risk for right ventricular outflow tract defects and atrial septal defect). It also cites risks of persistent pulmonary hypertension of the newborn (PPHN) and poor neonatal adaptation with SSRI exposure, complications in neonates exposed late in the third trimester (respiratory distress, feeding difficulty, jitteriness, seizures), and a less than 2-fold increased risk of postpartum hemorrhage when used in the month before delivery. The label states that for women who intend to become pregnant or who are in their first trimester, paroxetine should be initiated only after consideration of other available treatment options, and it also weighs the risk of untreated depression (relapse) in pregnancy. It does not tell patients to stop or start on their own — these decisions belong with the prescriber. This is what paroxetine's FDA label says; whether to use it in pregnancy is your prescriber's decision.

Under Metabolic and Nutritional adverse reactions, the label lists weight gain as a Frequent adverse reaction and weight loss as infrequent. So the label does report weight gain (categorized as frequent, without a precise percentage), alongside less common weight loss.

The label describes a Discontinuation Syndrome (Warnings and Precautions 5.7). Adverse reactions after stopping the drug, particularly after abrupt discontinuation, include nausea, sweating, dysphoric mood, irritability, agitation, dizziness, sensory disturbances such as paresthesia (electric-shock sensations), tremor, anxiety, confusion, headache, lethargy, emotional lability, insomnia, hypomania, tinnitus, and seizures. The label directs that the dosage be reduced gradually rather than stopped abruptly whenever possible, and that patients discuss any tapering regimen with their prescriber; it is a prescriber-managed taper. This discontinuation warning is not in the boxed warning (the boxed warning covers suicidal thoughts and behaviors). Do not stop paroxetine on your own — any change is a prescriber-managed decision.

The elimination half-life of paroxetine is about 21 hours on average (the label reports a mean of approximately 21 hours, with 32% variability between people) — that is how long the body takes to clear half of a dose. This is the mean elimination half-life measured after 30 mg daily for 30 days; the label gives a single mean with 32% coefficient of variation rather than a range, so individual values vary widely. No active metabolite to worry about: the label states paroxetine's metabolites "have no more than 1/50 the potency of the parent compound at inhibiting serotonin uptake," so the parent drug's half-life is the one that matters. Paroxetine is not a prodrug. Paroxetine's kinetics are non-linear — it partly saturates the enzyme (CYP2D6) that clears it, so exposure rises more than proportionally with higher doses and with longer treatment, and the effective half-life can be longer than 21 hours at higher doses. The label does not print a separate half-life number for special populations (it presents them in a figure), but it does say drug exposure is higher and that "the recommended starting dosage and maximum dosage of paroxetine is reduced in elderly patients, patients with severe renal impairment, and patients with severe hepatic impairment" — so expect the drug to linger longer than 21 hours in those groups. This figure describes how long the drug itself is cleared from the body; it is not a drug-test detection window and not dosing guidance. Half-life is not the same as how long a drug test can detect the drug, and it varies with age, kidney and liver function.

It depends on the medicine. We check it against the FDA labels rather than guessing: our interaction checker searches each drug's own label for the other and quotes what it says, naming the section it came from. Run paroxetine against whatever else you take — and remember that a label not naming a drug is not the same as that combination being safe.

We track 6 paroxetine-containing products in the U.S.: Paroxetine Mesylate, Paroxetine Hydrochloride, Paxil, Paxil CR, Brisdelle and Pexeva. They are the same active ingredient; they differ in form, manufacturer, price and FDA recall record.

Across the brands we track, paroxetine is currently marketed as capsule, suspension, tablet, extended release and tablet, per the FDA's National Drug Code Directory. Each form is dosed differently — follow the label for the exact product you were prescribed.

Yes. Our catalog lists 2 generic paroxetine products alongside the brand versions. A generic has the same active ingredient and must meet the FDA's bioequivalence standard; it usually costs less. Ask your pharmacist which one your plan covers.

It works gradually, not overnight. You may notice some early changes — sleep, appetite or energy — within the first 1 to 2 weeks, but the full effect on mood or anxiety usually takes about 4 to 6 weeks (sometimes up to 8). That delay is normal and is why prescribers ask you not to judge it too soon or stop early; give it time and stay in touch about side effects, and never stop abruptly.

Nausea, drowsiness, dry mouth, sweating, constipation, dizziness, and sexual side effects such as reduced desire or delayed orgasm. Paroxetine is among the SSRIs most likely to cause sexual dysfunction, weight gain, and drowsiness. Early effects like nausea often ease over one to two weeks, while sexual side effects and weight changes tend to persist.

Paroxetine carries a boxed warning for increased suicidal thinking and behavior in people under 25, seek help immediately for worsening mood, agitation, or self-harm thoughts, especially early on. Get emergency care for serotonin syndrome (agitation, fever, fast heart rate, muscle rigidity or twitching, shivering), for a severe allergic reaction, or for signs of low sodium (severe headache, confusion, weakness, unsteadiness), which is more common in older adults.

Paroxetine is generally avoided in pregnancy. Unlike most SSRIs, it has been linked to a higher risk of heart defects when taken in the first trimester, and it historically carried the FDA's pregnancy Category D designation (the letter categories have since been phased out of labeling in favor of a narrative risk summary). If you are pregnant or planning pregnancy, talk to your doctor before starting or stopping, do not stop suddenly on your own.

Paroxetine leaves the body quickly and has no long-acting active metabolite, so stopping it abruptly commonly causes discontinuation symptoms, dizziness, nausea, irritability, vivid dreams, and 'brain-zap' electric-shock sensations. These are uncomfortable but not usually dangerous. Always taper the dose gradually under your doctor's guidance rather than quitting cold.

Expected and usually temporary: mild nausea, sleepiness, dry mouth, and sweating, keep your prescriber updated but you generally don't stop. Contact your doctor promptly for easy bruising or bleeding (paroxetine can raise bleeding risk, especially with NSAIDs or blood thinners), a fast or irregular heartbeat, or confusion and weakness that could signal low sodium. Emergency signs are serotonin syndrome, a severe allergic reaction, or thoughts of self-harm.